Join the Lecanemab group to help and get support from people like you.
Lecanemab News
Lecanemab for Alzheimer Disease Safe, Feasible in Real-World Practice
THURSDAY, May 15, 2025 – Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory clinic, and the frequency of significant adverse events is similar to clinical trials,...
Anti-Amyloid Drug Shows Promise In Preventing Alzheimer's
MONDAY, March 24, 2025 – The best evidence yet that cutting-edge Alzheimer’s disease drugs might indeed ward off the degenerative brain disease has emerged from a small-scale study. An experimental d...
FDA Approves Leqembi (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., January 27, 2025 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Ch...
Annual Wasteful Spending on Lecanemab Estimated at $133 to $336 Million
FRIDAY, Oct. 18, 2024 – Annual wasteful spending on discarded lecanemab is anticipated to range between $133 and $336 million, given current vial sizes, according to a research letter published...
Lecanemab-Labeled Amyloid Plaques Identified in Down Syndrome
TUESDAY, Aug. 27, 2024 – In middle-aged individuals with Down syndrome (DS), lecanemab-labeled amyloid plaques are seen in postmortem brain tissue analysis, in addition to extensive binding to brain...
FDA Grants Traditional Approval for Leqembi (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas...
FDA Approves Leqembi (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with Leqembi™ Treatment with Leqembi should be initiated in patients with mild c...